David Fox

David Fox

Company: University of Michigan

Job title: Professor of Rheumatology and Professor of Internal Medicine


New Targets for the Treatment of Autoimmunity – CD6 & CD13 9:00 am

Ligands of CD6 include both CD166 (ALCAM) and CD318 Interruption of the interaction between CD6 and CD318 prevents or reverses autoimmune diseases driven by Th1 and/or Th17 cells Soluble CD13, shed from the surface of activated fibroblasts, is a powerful chemotactic, angiogenic and inflammation-inducing molecule, that acts through a GPCR Inhibitors of CD13 or its…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.